SEC EDGARSEP 41 min read$VCYT

Chambers Rebecca sold $157K of VCYT

Chambers Rebecca (Chief Financial Officer) sold 3,652 shares of VERACYTE, INC. (VCYT) at an average of $43.10 ($42.81–$43.71, $0.16M total) across 2 trades on 2026-09-04 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Chambers Rebecca

Published Sep 4, 2026, 11:54 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 4, 2026, 11:58 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$VCYT

Bearish

medium confidence

Mentioned

$VCYT

Relevance

3/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$VCYTBearishLow

Why it matters

A modest insider sell may cause slight negative sentiment but unlikely to move price materially.

Market read

Relevant for traders monitoring insider activity; limited trading impact.

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 3/10Novelty 3/10Timing: same-day filing

Background

Form 4 filing discloses insider transactions required by SEC.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$VCYTBearishMedium confidence

Context

CFO Rebecca Chambers sold 3,652 shares (~$157K) via a 10b5-1 plan on 2026-09-04.

Expected impact

Potential short-term pressure; limited upside.

Evidence & confidence

Sale amount is small relative to holdings; market may view as routine.

Market effects

Sector

Minor impact on biotech diagnostics sector; no broader trend.

Regional

Limited to US market where VCYT trades.

Global

Low; only affects VCYT shareholders.

Counterpoint

What could challenge this read

The sale could be a routine liquidity move, not a bearish signal.

Key entities

Company
Veracyte, Inc.
Biotech diagnostics firm listed on NASDAQ.
Executive
Rebecca Chambers
Chief Financial Officer of Veracyte.

Read at source ← All news

OCT 23

$VCYTMedAI 8/10

Veracyte, Inc. (VCYT) Decipher Test Shown to Predict Abiraterone Benefit in Very High-Risk Prostate Cancer

Veracyte reported that its Decipher Prostate test can predict which very high-risk nonmetastatic prostate cancer patients may benefit from adding abiraterone to ADT, based on a retrospective Phase III STAMPEDE analysis. The test's evidence base now extends to predicting treatment benefit, not just risk stratification.

tradingview.com2 min

OCT 23

$VCYTMedAI 8/10

An 11% five-year benefit against prostate cancer spread came with added treatment for men with very high test scores.

Veracyte (VCYT) announced new data showing its Decipher Prostate Genomic Classifier can predict benefit from adding abiraterone to ADT in high-risk prostate cancer patients. The analysis, presented at ESMO 2026, showed 11% 5-year benefit in reducing metastasis for high-risk patients. The findings support broader adoption of Decipher in treatment decisions.

stocktitan.net2 min

OCT 16

$VCYTMed

Veracyte, Inc. (VCYT) Wins Medicare Coverage for Prosigna Test

Veracyte (VCYT) announced Medicare coverage for its Prosigna Breast Cancer test, effective August 19, 2026, for eligible patients. The decision marks an early commercialization milestone, according to the company.

tradingview.com1 min

OCT 16

$VCYTMed

A breast cancer test could spare chemotherapy for more than two-thirds of clinically high-risk patients

Veracyte's Prosigna test for early-stage breast cancer received Medicare coverage, enabling reimbursement for eligible patients. The test helps determine chemotherapy necessity, sparing over two-thirds of high-risk patients, per the OPTIMA trial. Veracyte (VCYT) aims for broader adoption and access.

stocktitan.net2 min

SEP 14

$VCYTHigh

VERACYTE, INC. (VCYT): Completion of Acquisition or Disposition of Assets

VERACYTE, INC. (VCYT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the

SEC EDGAR 8-K2 min

JUL 30